Posicor: Veni, vidi and gone;Posicor: Veni, vidi, foetsie

Pharmaceutisch Weekblad

Volumn 133, Issue 35, 1998, Pages 1294-1295

  Duchateau, A M J A ^a  

^a Ziekenhuisapotheek ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; AMLODIPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CARBAMAZEPINE; CIMETIDINE; CISAPRIDE; CLOZAPINE; CYTOCHROME P450 ISOENZYME; DICLOFENAC; DICOUMAROL; DILTIAZEM; ESTRADIOL; FLUOXETINE; FLUVOXAMINE; ITRACONAZOLE; METOPROLOL; MIBEFRADIL; NIFEDIPINE; NISOLDIPINE; PROGUANIL; PROPRANOLOL; RIFAMPICIN; SERTRALINE; SIMVASTATIN; TERFENADINE; THEOPHYLLINE; TOLBUTAMIDE; UNINDEXED DRUG; WARFARIN;

ANGINA PECTORIS; DRUG INDICATION; DRUG METABOLISM; DRUG WITHDRAWAL; HEART ARRHYTHMIA; HEART FAILURE; HUMAN; HYPERTENSION; MORTALITY; NOTE; TORSADE DES POINTES;

EID: 0032575561     PISSN: 00316911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (6)

1. Roche withdraws Posicor on drug interaction issue. Marketletter 1998 jun 15:19.
2. Jessop DJ. What lessons can be learnt from withdrawal of mibefradil from the market? Lancet 1998;351:1829-30.
3. Mullins ME, Horowitz BZ, Linden DHL, et al. Life-threatening interaction of mibefradil and betablockers with dihydropyridine calcium channel blockers. JAMA 1998;280:157-8.
4. Touw DJ, Breimer DD Het cytochroom P450-enzymsysteem. Een familie met acties, reacties en interacties Deel 1. Pharm Weekbl 1997;132(28):948-63.
5. Touw DJ, Breimer DD. Het cytochroom P450-enzymsysteem. Een familie met acties, reacties en interacties. Deel 2. Pharm Weekbl 1997;132(29):996-1009.
6. Bertz J, Granneman GR. Use of in vitro and in vivo data to estimate the likelyhood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 1997;32:210-58.